Insulcloud Secures FDA Clearance to Launch Insulclock® CAP in the U.S., Transforming Diabetes Care
Insulcloud, a healthtech innovator focused on diabetes management, has received FDA clearance for its Insulclock® CAP, marking a key milestone in the company’s expansion into the U.S. market. This advanced device upgrades disposable insulin pens with real-time monitoring capabilities, helping millions of Americans living with diabetes optimize their insulin therapy. The Insulclock CAP ensures higher adherence by providing timely visual and audible reminders, contributing to better health outcomes and cost savings.
“Our smart pen cap empowers patients to manage diabetes with greater precision while helping insurers reduce complications and hospitalizations,” said Judith Ruiz de Esquide, General Manager of Insulcloud. “At Insulcloud, we are committed to making life-changing technology accessible to everyone and transforming diabetes care for a healthier future.” Already used across Europe by thousands, the Insulclock CAP captures essential data such as dosage, injection timing, and insulin temperature, while distinguishing bolus from priming doses automatically. Peer-reviewed studies validate a 13.5% improvement in on-time injections, with users seeing an average annual cost saving of $1,000 per patient.
Designed to work with all major insulin brands, the Insulclock CAP connects with a companion app for seamless tracking. It integrates easily into healthcare systems through its FDA-approved software development kit (SDK). Insulcloud is now actively exploring distribution partnerships in the U.S. and considering establishing its first international office in Boston, enhancing its global footprint.
